03.01.2019

ASCO-SITC Clinical Immuno-Oncology Symposium (2019)

A Phase II Trial with the Combination of Plinabulin (Plin) Pegfilgrastim (Peg): Evaluation of the Reversal of Peg’s Immune-Suppressive Potential by the Addition of Plinto Peg